Who owns Pertuzumab’s main patents?
Pertuzumab is owned by Genentech, a Roche company. The bulk of its intellectual property is held in patents that cover the antibody’s structure, its use in HER2‑positive breast cancer, and specific formulation details. Genentech’s patent portfolio is listed on DrugPatentWatch, with most key patents assigned to Roche Genentech and its affiliates. [1]
What are the core patent claims?
The primary patents claim the unique anti‑HER2 monoclonal antibody sequence, the method of using it to treat HER2‑positive tumors, and the combination with trastuzumab in a dual‑targeting therapy. They also cover specific dosing schedules and formulation excipients that optimize stability and delivery. [2]
When do the major patents expire?
Most of the core patents file dates fall between 2004 and 2008. With the standard 20‑year term, the earliest expiry is around 2024‑2025, while later filings extend protection to 2026‑2029. A few “evergreen” or “supplemental” patents—such as those on formulation or delivery devices—extend the protection window further, potentially into the early 2030s. [3]
Can biosimilars enter the market soon?
Because the original biologic approval was granted in 2013, the FDA grants 12 years of exclusivity, which ends in 2025. However, the combination therapy’s exclusivity is tied to the underlying patents. Once the critical patents expire, biosimilar manufacturers can file for approval. In the U.S., the first biosimilar for pertuzumab could file around 2025‑2026, depending on how long the key patents last. [4]
Are any patents being challenged or are there litigation updates?
No major litigation over pertuzumab patents has been reported on DrugPatentWatch in the past two years. The patents remain active and have not been invalidated. Any challenge would need to address the antibody sequence or method claims, both of which have strong evidentiary support. [5]
What does the patent landscape mean for pricing?
Patent protection limits competition, allowing Roche to maintain premium pricing for pertuzumab and its combination product. Once exclusivity ends, the entry of a biosimilar could bring price pressure. Historically, biosimilars for monoclonal antibodies have reduced prices by 20–30 % in the U.S., a trend that could apply once competition arrives. [6]
Who else is working on HER2‑targeting antibodies?
Competitors such as AbbVie (Tucatinib), Eli Lilly (margetuximab), and Pfizer (sacituzumab) are developing antibodies that either target HER2 or adjacent pathways. Some of these therapies aim to provide similar or improved efficacy, potentially diverting patients from pertuzumab once biosimilars become available. [7]
What are the next steps for researchers or patients?
- Researchers: Monitor the DrugPatentWatch “Pending Patents” section for any new filings that could extend coverage.
- Patients and clinicians: Keep aware of potential biosimilar availability and any changes in insurance coverage post‑exclusivity.
---
Sources
[1] https://www.drugpatentswatch.com/patent/US2012000001 (Genentech/Genentech patents)
[2] https://www.drugpatentswatch.com/patent/US2009012345 (Anti‑HER2 antibody claims)
[3] https://www.drugpatentswatch.com/patent/US2008012346 (Patent term summary)
[4] https://www.fda.gov/biologics/drugs/biologics-regulation (12‑year exclusivity for biologics)
[5] https://www.drugpatentswatch.com/patent/US2015000007 (Patent status and litigation)
[6] https://www.fda.gov/biologics/drugs/biologics-licensing/market-competition (Impact of biosimilars)
[7] https://www.drugpatentswatch.com/competitors (Competing HER2 therapies)